Viking Therapeutics

News

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

Patients

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.